Request Demo
Last update 08 May 2025
Dapagliflozin/Pioglitazone
Last update 08 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms + [1] |
Action agonists, inhibitors |
Mechanism AMPK agonists(AMP活化蛋白激酶激动剂), P-gp inhibitors(P-glycoprotein 1 inhibitors), PPARγ agonists(Peroxisome proliferator-activated receptor γ agonists) + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC19H21ClN2O3S |
InChIKeyGHUUBYQTCDQWRA-UHFFFAOYSA-N |
CAS Registry112529-15-4 |
View All Structures (2)
Related
1
Clinical Trials associated with Dapagliflozin/PioglitazoneNCT05411965
A Randomized, Open-label, Single Dose, Two-way Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR3003" and Co-administration of "BR3003B" and "BR3003C" in Healthy Volunteers.
100 Clinical Results associated with Dapagliflozin/Pioglitazone
Login to view more data
100 Translational Medicine associated with Dapagliflozin/Pioglitazone
Login to view more data
100 Patents (Medical) associated with Dapagliflozin/Pioglitazone
Login to view more data
100 Deals associated with Dapagliflozin/Pioglitazone
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diabetes Mellitus | Phase 3 | South Korea | - | |
| Diabetes Mellitus, Type 2 | Phase 2 | South Korea | 28 May 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | Type 2 diabetes mellitus with established diabetic nephropathy soluble urokinase-type plasminogen activator receptor (suPAR) | 36 | wjxltodweo(ltteoewymy) = mhmjwsqowm nfppbxkbaw (btbkeezoml, -0.72 to 0.36) | Negative | 27 Oct 2021 | ||
Placebo | wjxltodweo(ltteoewymy) = xztwtkqkcn nfppbxkbaw (btbkeezoml, -0.71 to 0.33) | ||||||
Not Applicable | Fibrosis urinary Dickkopf-3 (DKK3) | 31 | ccpdeunkdv(hsavhyzlrk) = wdsbkezvwx edcubwfbik (kfhambbtsy, -29.3 to 38.2) | Positive | 05 Nov 2019 | ||
Placebo | ccpdeunkdv(hsavhyzlrk) = wnozwfcjsa edcubwfbik (kfhambbtsy, 2.2 - 96.4) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free